846 Shares in Elevance Health, Inc. (NYSE:ELV) Bought by Client 1ST Advisory Group LLC

Client 1ST Advisory Group LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 846 shares of the company’s stock, valued at approximately $312,000.

Other large investors also recently bought and sold shares of the company. Grove Bank & Trust boosted its position in Elevance Health by 354.1% in the 4th quarter. Grove Bank & Trust now owns 2,575 shares of the company’s stock valued at $950,000 after buying an additional 2,008 shares during the period. Steigerwald Gordon & Koch Inc. boosted its position in Elevance Health by 2.8% during the 4th quarter. Steigerwald Gordon & Koch Inc. now owns 44,453 shares of the company’s stock valued at $16,399,000 after acquiring an additional 1,222 shares in the last quarter. Liberty One Investment Management LLC grew its stake in Elevance Health by 13.7% in the fourth quarter. Liberty One Investment Management LLC now owns 9,079 shares of the company’s stock valued at $3,349,000 after purchasing an additional 1,096 shares during the last quarter. HF Advisory Group LLC grew its position in shares of Elevance Health by 35.9% in the 4th quarter. HF Advisory Group LLC now owns 5,070 shares of the company’s stock worth $1,870,000 after buying an additional 1,339 shares during the last quarter. Finally, Arkadios Wealth Advisors grew its holdings in Elevance Health by 11.5% in the fourth quarter. Arkadios Wealth Advisors now owns 1,107 shares of the company’s stock worth $408,000 after purchasing an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

ELV has been the topic of several recent analyst reports. Morgan Stanley cut their price objective on shares of Elevance Health from $643.00 to $551.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on Elevance Health from $585.00 to $478.00 and set an “outperform” rating for the company in a research note on Friday, October 18th. Truist Financial decreased their target price on shares of Elevance Health from $520.00 to $480.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Cantor Fitzgerald dropped their price target on shares of Elevance Health from $600.00 to $485.00 and set an “overweight” rating on the stock in a research report on Friday, October 18th. Finally, Barclays decreased their price objective on shares of Elevance Health from $622.00 to $501.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $536.53.

Elevance Health Stock Performance

NYSE ELV opened at $384.26 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The company has a market cap of $89.12 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 1.08 and a beta of 0.84. The stock’s 50 day simple moving average is $388.02 and its 200-day simple moving average is $466.63.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.66 by ($1.29). The business had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $8.99 EPS. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 32.96 EPS for the current fiscal year.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.